Published in AIDS Weekly, September 16th, 1996
Depending on how it is formulated and administered, the immunogen can stimulate either serum or mucosal immune responses in animal studies.
"We hope, if all goes well, to do a Phase I clinical trial in HIV seronegatives," said Thomas C. VanCott of the Henry M. Jackson Foundation, Rockville, Maryland.
VanCott described the immunogen, called oligomeric gp160 or ogp160, in a presentation to the XI International Conference on AIDS, held July 7-12, 1996, in Vancouver, British Columbia, Canada.
...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1996-09-16)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.